Risk factors
Akari Therapeutics (AKTX) risk factors
Item 1A of every Akari Therapeutics plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors46 risks2 new22 dropped13 reworded
Akari Therapeutics increased its reported cash to $5.2 million as of December 31, 2025.
Filed Mar 30, 2026 - FY2024 10-K risk factors66 risks
Akari Therapeutics faces substantial operating losses and negative cash flows, with only $2.6 million in cash as of December 31, 2024. The company is heavily dependent on third-party contractors for clinical trials and manufacturing. Regulatory hurdles, complex intellectual property protection, and foreign market requirements dominate the risk profile.
Filed Apr 15, 2025